What is Rhythm Pharmaceuticals?
Rhythm Pharmaceuticals is a specialized biopharmaceutical research and development organization dedicated to the discovery and commercialization of precision medicines. Founded in 2008, the company focuses on the underlying genetic causes of rare obesity disorders, specifically those involving the melanocortin-4 receptor pathway. By bridging the gap between complex genetic science and therapeutic application, Rhythm Pharmaceuticals addresses significant unmet medical needs for patients suffering from severe, chronic conditions. The company maintains a strategic operational presence in key global markets, including the Netherlands and France, ensuring a comprehensive approach to international clinical trials and regulatory engagement.
How much funding has Rhythm Pharmaceuticals raised?
Rhythm Pharmaceuticals has raised a total of $848.5M across 8 funding rounds:
Series A
$40M
Series B
$33M
Other Financing Round
$41M
Stock Offering
$138M
Stock Offering
$174M
Stock Offering
$172.5M
Debt
$100M
Series A
$150M
Series A (2010): $40M with participation from MPM Capital, Third Rock Ventures, and New Enterprise Associates (NEA)
Series B (2012): $33M led by NEA, MPM Capital, Third Rock Ventures, Pfizer Venture Investments, and Ipsen
Other Financing Round (2017): $41M supported by MPM Capital, Pfizer Venture Investments, OrbiMed, Third Rock Ventures, Ipsen, Deerfield, and NEA
Stock Issuance/Offering (2017): $138M featuring Undisclosed
Stock Issuance/Offering (2018): $174M backed by Undisclosed
Stock Issuance/Offering (2019): $172.5M with participation from Undisclosed
Debt (2022): $100M led by HealthCare Royalty Partners
Series A (2024): $150M supported by Perceptive Advisors
Key Investors in Rhythm Pharmaceuticals
MPM Capital
MPM BioImpact manages early-stage venture funds, private/public impact funds and a public equities fund. We convert science into therapeutics to reach the patients that need them most.
Third Rock Ventures
Founded in 2007, Third Rock Ventures is a healthcare venture firm focused on disruptive areas of science and medicine to discover, launch and build companies that make a dramatic difference in people's lives.
OrbiMed
OrbiMed Advisors LLC operates as a specialized investment firm focused on the healthcare sector, with deep expertise spanning multiple therapeutic and commercial domains.
What's next for Rhythm Pharmaceuticals?
With the recent capital injection, Rhythm Pharmaceuticals is well-positioned to scale its research initiatives and optimize its commercialization strategy. The focus remains on advancing its therapeutic portfolio through late-stage clinical trials while leveraging its deep expertise in genetic metabolic disorders. Future strategic priorities include the expansion of its precision medicine platform and the potential for new partnerships to enhance its global market reach. As the company matures, it will likely continue to prioritize data-driven innovation, ensuring that its pipeline remains at the forefront of biopharmaceutical development. The firm's ability to secure consistent backing from top-tier healthcare investors suggests a sustainable path toward long-term value creation for both patients and stakeholders in the life sciences sector.
See full Rhythm Pharmaceuticals company page
